Adjuvant radiotherapy improved disease-free survival in atypical meningioma trial

The ROAM/EORTC-1308 phase 3 randomised trial compared adjuvant radiotherapy versus observation in 157 patients with newly diagnosed WHO grade 2 atypical meningioma after complete surgical resection. At a median follow-up of 64 months, the trial reported recurrence in 14% of the radiotherapy group versus 30% of the observation group, with 5-year disease-free survival of 79.9% versus 64.3% and a hazard ratio of 0.51 favoring radiotherapy. Grade 2 or 3 radiation-related serious adverse events occurred in 8% of treated participants, with no treatment-related deaths reported.

Most relevant for: Patients with newly diagnosed WHO grade 2 atypical meningioma who have undergone complete surgical resection.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.